Abstract
Three platinum (II) complexes (6-8) with phthalate as the leaving group were synthesized and characterized by FTIR, 1H NMR, 13C NMR, mass spectrometry and elemental analysis. In-vitro cytotoxicity of all three complexes was evaluated using COLO 205 (human colon cancer cell line) against the parent drug “oxaliplatin”. The compound 4-amino-(transcyclohexane- 1,2-diamine) platinum(II) (8) showed potent cytotoxicity with IC50 = 0.12 µM as compared to oxaliplatin (IC50 = 0.19 µM) and its aqueous solubility was found to be 16 mg/mL which is higher than oxaliplatin (8 mg/mL). The acute toxicity showed that the platinum complex (8) was less toxic than oxaliplatin. Molecular oxaliplatin-DNA complex structure indicates that the diaminocyclohexane (DACH) and Pt (II) showed interactions with N7 and O6 of GG base pairs of DNA helix. In this present study, it is interesting to note that all three platinum based anticancer agents with phthalate as the leaving group exhibited great cytotoxicity, less toxicity, good lipophilicity as well as better aqueous solubility.
Keywords: Cytotoxicity, Lipophilicity, Oxaliplatin, Platinum complexes, trans-(±)-1, 2-Diaminocyclohexane.
Letters in Drug Design & Discovery
Title:Design, Synthesis and In-Vitro Cytotoxicity of Novel Platinum (II) Complexes with Phthalate as the Leaving Group
Volume: 10 Issue: 9
Author(s): Rajiv Sharma, Ravindra K. Rawal, Manav Malhotra, Tripti Gaba, A. K. Sharma and T. R. Bhardwaj
Affiliation:
Keywords: Cytotoxicity, Lipophilicity, Oxaliplatin, Platinum complexes, trans-(±)-1, 2-Diaminocyclohexane.
Abstract: Three platinum (II) complexes (6-8) with phthalate as the leaving group were synthesized and characterized by FTIR, 1H NMR, 13C NMR, mass spectrometry and elemental analysis. In-vitro cytotoxicity of all three complexes was evaluated using COLO 205 (human colon cancer cell line) against the parent drug “oxaliplatin”. The compound 4-amino-(transcyclohexane- 1,2-diamine) platinum(II) (8) showed potent cytotoxicity with IC50 = 0.12 µM as compared to oxaliplatin (IC50 = 0.19 µM) and its aqueous solubility was found to be 16 mg/mL which is higher than oxaliplatin (8 mg/mL). The acute toxicity showed that the platinum complex (8) was less toxic than oxaliplatin. Molecular oxaliplatin-DNA complex structure indicates that the diaminocyclohexane (DACH) and Pt (II) showed interactions with N7 and O6 of GG base pairs of DNA helix. In this present study, it is interesting to note that all three platinum based anticancer agents with phthalate as the leaving group exhibited great cytotoxicity, less toxicity, good lipophilicity as well as better aqueous solubility.
Export Options
About this article
Cite this article as:
Sharma Rajiv, Rawal K. Ravindra, Malhotra Manav, Gaba Tripti, Sharma K. A. and Bhardwaj R. T., Design, Synthesis and In-Vitro Cytotoxicity of Novel Platinum (II) Complexes with Phthalate as the Leaving Group, Letters in Drug Design & Discovery 2013; 10 (9) . https://dx.doi.org/10.2174/15701808113109990018
DOI https://dx.doi.org/10.2174/15701808113109990018 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Function of the Selective Inhibitors of Cycloxygenase 2
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: PET/CT in External Beam Radiation Therapy Dose Planning)
Current Radiopharmaceuticals Radio-Susceptibility of Nasopharyngeal Carcinoma: Focus on Epstein- Barr Virus, MicroRNAs, Long Non-Coding RNAs and Circular RNAs
Current Molecular Pharmacology Zebrafish as a Model System to Screen Radiation Modifiers
Current Genomics Clinically Relevant Genetic Variations in Drug Metabolizing Enzymes
Current Drug Metabolism Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety The Return of the INGs, Histone Mark Sensors and Phospholipid Signaling Effectors
Current Drug Targets Emerging Therapies in the Treatment of Locally Advanced Squamous Cell Cancers of Head and Neck
Recent Patents on Anti-Cancer Drug Discovery An Update on JAK Inhibitors
Current Medicinal Chemistry Theoretical Studies on Binding and Specificity Mechanisms of Farnesyltransferase (FTase) and Geranylgeranyltransferase Type-I (GGTase-I) Inhibitors by Molecular Modeling
Combinatorial Chemistry & High Throughput Screening Factors Affecting Quantification in PET/CT Imaging
Current Medical Imaging Surgical Management of Medullary Thyroid Carcinoma in Pediatric Age
Current Pediatric Reviews In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome
Recent Patents on Anti-Cancer Drug Discovery Targeting the Perpetrator: Breast Cancer Stem Cell Therapeutics
Current Drug Targets Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design NF-κB Inhibitors in Head and Neck Cancer
Letters in Drug Design & Discovery New and Highly Potent Antitumor Natural Products from Marine-Derived Fungi: Covering the Period from 2003 to 2012
Current Topics in Medicinal Chemistry An Overview on Keratinocyte Growth Factor: From the Molecular Properties to Clinical Applications
Protein & Peptide Letters